Aethlon In Ebola Fray, CMN Opens Wallet, CEMP On Watchlist, KOOL Yet To Heat Up

(RTTNews) - Aethlon Medical Inc. (AEMD.OB) closed Friday's trading 44 per cent higher after the company announced that the FDA has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with its investigational bio-filtration device Hemopurifier.

The approved Ebola treatment protocol allows for an investigational study to be conducted at up to 10 U.S. clinical sites, and up to 20 U.S. subjects may be enrolled to receive the treatment protocol.

The company noted that patients who meet the enrollment criteria will receive a daily six to eight hour administration of Hemopurifier therapy until the point that Ebola viral load drops below 1000 copies/ml. The goal of the study is to standardize and evaluate the use of the Hemopurifier as supportive care in the treatment of Ebola virus disease.

According to the World Health organization, the current outbreak in West Africa is the largest and most complex Ebola outbreak since the Ebola virus was first discovered in 1976. The total death toll from the Ebola outbreak has crossed 8,000.

AEMD.OB closed Friday's trading 44.11% higher at $0.38.

Cantel Medical Corp. (CMN), which markets and distributes medical equipment and infection control products, has acquired the assets of Pure Water Solutions Inc. for $11.9 million in cash, further enhancing its national water purification and filtration geographic footprint in the south-eastern U.S.

Pure Water Solutions provides water purification and treatment services for commercial and industrial, laboratory and medical customers out of eight regional offices throughout the South-eastern United States.

Cantel expects the transaction to be neutral to its GAAP EPS in FY15 and slightly accretive to its non-GAAP EPS in FY15, and is expected to be accretive on both a GAAP and non-GAAP basis thereafter. (Non-GAAP EPS represents Earnings Per Share excluding acquisition-related intangible amortization as well as transaction-related expenses).

CMN closed Friday's trading at $42.73, down 1.23%.

Cempra Inc. (CEMP) is a stock to keep an eye on for Monday's trading session as the company has reported positive top line phase III clinical results of its drug candidate oral Solithromycin in the treatment of community acquired bacterial pneumonia.

In the phase III trial, dubbed Solitaire-Oral, Solithromycin met the primary objective of statistical non-inferiority of the early clinical response at 72 hours after initiation of therapy compared to the approved antibiotic moxifloxacin.

According to the trial results, the primary endpoint of early clinical response was 78.2% for Solithromycin and 77.9% for moxifloxacin in the Solitaire-Oral trial.

A second phase III trial of Solithromycin, known as Solitaire-intravenous, which was initiated in December 2013, is underway, and is enrolling patients as planned.

CEMP closed Friday's trading at $22.89, down 2.64%.

Cesca Therapeutics Inc. (KOOL) has received feedback from the FDA related to its investigational device exemption application for its pivotal clinical trial of SurgWerks-CLI and VXP System for treating advanced stages of no-option lower limb critical limb ischemia.

In its letter, the FDA noted several deficiencies in the company's submission, requesting, among other things, additional information on characterization of the output of the SurgWerks - CLI and VXP system.

The company expects to submit its amended investigational device exemption application sometime in February 2015. If the amended application is approved by the FDA, Cesca hopes to begin enrolling patients as early as April 2015.

KOOL closed Friday's trading at $1.03, up 0.98%.